title: Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation.
abstract: We assessed long-term outcome in 155 patients who had undergone an allogeneic/syngeneic stem cell transplant (SCT) and were in complete remission for more than 2 years after transplant. Probability of late transplant-related mortality was 6%, and affected only patients with chronic graft-versus-host disease (cGVHD). Thirteen percent of patients experienced relapse. Overall survival projected at 10 and 15 years was 83% and 76%, respectively. Secondary malignancies occurred in two patients, 7.5 and 11 years after SCT. Three female and four male patients parented children 19 to 84 months after SCT. Quality of life (QoL) was assessed in a cross-sectional study by the means of a 30-item questionnaire (QLQ-C30) of the EORTC. The questionnaire was sent to 127 patients remaining alive and answered by 106 patients. Seventy-three percent reported a good to very good QoL within 5 years after SCT and 78% after this time point. However, patients with cGVHD had significant impairment of physical, role and social functioning and only 60% of them were fit for work. These results from long-term survivors show that high cure rates with good to very good QoL can be achieved by allogeneic or syngeneic SCT.
authors.affiliation: Department of Medicine I, Bone Marrow Transplantation Unit, University of Vienna, Austria.
authors.forename: N
authors.initials: N
authors.lastname: Worel
authors.forename: D
authors.initials: D
authors.lastname: Biener
authors.forename: P
authors.initials: P
authors.lastname: Kalhs
authors.forename: M
authors.initials: M
authors.lastname: Mitterbauer
authors.forename: F
authors.initials: F
authors.lastname: Keil
authors.forename: A
authors.initials: A
authors.lastname: Schulenburg
authors.forename: P
authors.initials: P
authors.lastname: Höcker
authors.forename: K
authors.initials: K
authors.lastname: Dieckmann
authors.forename: G
authors.initials: G
authors.lastname: Fischer
authors.forename: A
authors.initials: A
authors.lastname: Rosenmayr
authors.forename: W
authors.initials: W
authors.lastname: Linkesch
authors.forename: W
authors.initials: W
authors.lastname: Hinterberger
authors.forename: K
authors.initials: K
authors.lastname: Lechner
authors.forename: H T
authors.initials: HT
authors.lastname: Greinix
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006086:Graft vs Host Disease; D006402:Hematologic Diseases / Q000150:complications / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D011788:Quality of Life; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D016019:Survival Analysis; D013997:Time Factors; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic; D016896:Treatment Outcome